Document Detail


Critical evaluation of the efficacy and tolerability of azilsartan.
MedLine Citation:
PMID:  22661897     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.
Authors:
Alberto R De Caterina; Andrew R Harper; Florim Cuculi
Related Documents :
20822427 - Impedance cardiography facilitates differentiation of severe and superimposed preeclamp...
15643137 - Stiffness of the arterial wall, joints and skin in women with a history of pre-eclampsia.
7721397 - Job status and high-effort coping influence work blood pressure in women and blacks.
22302247 - Long-term blood pressure control: is there a set-point in the brain?
6996627 - Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension.
10385857 - The fast flush test--is the clinical comparison equivalent to its in vitro simulation?
Publication Detail:
Type:  Journal Article; Review     Date:  2012-05-14
Journal Detail:
Title:  Vascular health and risk management     Volume:  8     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2012  
Date Detail:
Created Date:  2012-06-04     Completed Date:  2012-09-04     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  299-305     Citation Subset:  IM    
Affiliation:
Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy. adecatro@yahoo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / adverse effects,  pharmacokinetics,  therapeutic use*
Animals
Antihypertensive Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Benzimidazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Blood Pressure / drug effects*
Drug Interactions
Evidence-Based Medicine
Humans
Hypertension / drug therapy*,  physiopathology
Oxadiazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Renin-Angiotensin System / drug effects
Risk Assessment
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Oxadiazoles; 0/azilsartan medoxomil; F9NUX55P23/azilsartan
Comments/Corrections
Erratum In:
Vasc Health Risk Manag. 2012;8:443-5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Smoking status and sex as indicators of differences in 2582 obese patients presenting for weight man...
Next Document:  Use of carvedilol in hypertension: an update.